Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000663

Drug Information
NameSirolimus    
SynonymsCID5924240; Perceiva; heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; nchembio883-comp3; SILA 9268A; DivK1c_006936; KBioGR_000410; Rapamycin Immunosuppressant Drug; AY-22989; UNM-0000358684; MLS000028373; (6H,31H)-pentone, 4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-; Sirolimus [USAN:BAN:INN]; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-; NCI60_001851; Sirolimus, Rapamune,Rapamycin; CID5497196; CID5374464; DB00877; Bio2_000855; KBio1_001880; nchembio.79-comp1; Bio2_000375; CID6610346; CID9854379; D00753; Rapamune; CID10795871; Bio1_000782; KBio3_000780; Rapamycin (TN); 1pbk; SMR000058564; C07909; (3-(4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-; CID6711160; CID9854380; MolMap_000043; KBio2_002978; Sirolimus (USAN/INN); WY-090217; SpecPlus_000840; CID5358081; CHEMBL413; LS-143290; CCRIS 9024; Rapamune (TN); NSC 226080; CID9962928; DE-109; R0395_SIAL; CHEBI:100923; Sirolimus (RAPAMUNE); 1fkb; Sirolimus; MS-R001; CBiol_002007; CID6610270; nchembio762-comp1; BiomolKI2_000084; KBio2_000410; HSDB 7284; CID5284616; 53123-88-9; AC1L9ZMV; NCIMech_000355; CID9833581; 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-; rapamycin; Bio1_000293; CID11959112; CID5040; KBio2_005546; CID5460439; CID10213190; NCGC00021305-05; 19E,21R*,23R*,26S*,27S*,34aR*))-; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; CID313006; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; FT-0082351; RPM; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; RAP; QTL1_000069; Ambotz53123-88-9; Rapamycin C-7, analog 4; (-)-Rapamycin; SIIA 9268A; UNII-W36ZG6FT64; R0395_SIGMA; C51H79NO13; BIDD:PXR0165; S1039_Selleck; nchembio.100-comp4; CID9962926; Bio1_001271; RAPA; KBioSS_000410; nchembio.2007.42-comp2; LMPK06000003; CHEBI:9168; CID6436030; SMP1_000255; Rapamycin from Streptomyces hygroscopicus; AC1L1JH9; AC-722; A422989, NSC226080; AY 22989; HMS2089A21; CID11949238; NSC226080; CID478951; Rapammune; Antibiotic AY 22989; LCP-Siro; MolPort-003-959-433; Wy 090217; AC1L7MJ9; KBio3_000779; CID6713081    
Trade NameRapamune    
CompanyWyeth    
IndicationDutch Elm diseasePhase I/II    [1]
Organ rejectionApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassImmunosuppressive Agents    
CAS NumberCAS 53123-88-9
FormularC51H79NO13    
PubChem Compound IDCID 6436030.    
PubChem Substance IDSID 207443.    
ChEBI9168;    
SuperDrug ATC IDL04AA10;    
SuperDrug CAS ID053123889;    
TargetSerine/threonine-protein kinase mTORInhibitor[2]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Nat Rev Drug Discov. 2003 Jan;2(1):38-51.Knockouts model the 100 best-selling drugs--will they model the next 100? To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543